Maravai LifeSciences Holdings Inc Ordinary Shares - Class A MRVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRVI is a good fit for your portfolio.
News
-
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024
-
Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report
-
TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
-
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
-
Maravai LifeSciences Reports First Quarter 2024 Financial Results
-
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
Trading Information
- Previous Close Price
- $8.51
- Day Range
- $8.58–9.19
- 52-Week Range
- $4.52–12.11
- Bid/Ask
- $8.91 / $9.48
- Market Cap
- $1.22 Bil
- Volume/Avg
- 1.3 Mil / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 162.41
- Price/Sales
- 4.41
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 570
- Website
- https://www.maravai.com
Comparables
Valuation
|
Metric
|
MRVI
|
TIHE
|
688399
|
|---|---|---|---|
Price/Earnings (Normalized) | 162.41 | — | — |
Price/Book Value | 2.96 | — | 1.22 |
Price/Sales | 4.41 | — | 10.53 |
Price/Cash Flow | 87.53 | — | 25.38 |
Price/Earnings
MRVI
TIHE
688399
Financial Strength
|
Metric
|
MRVI
|
TIHE
|
688399
|
|---|---|---|---|
Quick Ratio | 10.19 | — | 5.97 |
Current Ratio | 11.32 | — | 6.28 |
Interest Coverage | 13.71 | — | −51.83 |
Quick Ratio
MRVI
TIHE
688399
Profitability
|
Metric
|
MRVI
|
TIHE
|
688399
|
|---|---|---|---|
Return on Assets (Normalized) | −0.31% | — | −8.92% |
Return on Equity (Normalized) | −1.28% | — | −10.60% |
Return on Invested Capital (Normalized) | 0.45% | — | −11.13% |
Return on Assets
MRVI
TIHE
688399
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Wrbjcvlny | Xhqcc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yhwfhvqr | Kgcqwl | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rmvqwzntc | Xtfbz | $118.7 Bil | |||
| Moderna Inc
MRNA
| Cpwchdpk | Gkqgh | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ffyhwdf | Jstfd | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lpllvnyh | Hhljg | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Xjqdxxv | Xblk | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dmjnjmm | Qxbvqrn | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Bwfqxbyt | Vxkx | $15.0 Bil | |||
| Incyte Corp
INCY
| Lylzfrzy | Bvlvbq | $13.5 Bil |